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Abstract
Objectives—Current cochlear implants (CIs) have telemetry capabilities for measuring the
electrically evoked compound action potential (ECAP). Neural Response Telemetry (NRT™;
Cochlear) and Neural Response Imaging (NRI; Advanced Bionics [AB]) can measure ECAP
responses across a range of stimulus levels to obtain an amplitude growth function. Software-
specific algorithms automatically mark the leading negative peak, N1, and the following positive
peak/plateau, P2, and apply linear regression to estimate ECAP threshold. Alternatively, clinicians
may apply expert judgments to modify the peak markers placed by the software algorithms, and/or
use visual detection to identify the lowest level yielding a measurable ECAP response. The goals
of this study were to: (1) assess the variability between human and computer decisions for (a)
marking N1 and P2, and (b) determination of linear regression threshold (LRT) and visual
detection threshold (VDT); and (2) compare LRT and VDT methods within and across human and
computer decision methods.
Design—ECAP amplitude growth functions were measured for three electrodes in each of 20
ears (10 Cochlear Nucleus® 24RE/CI512, and 10 AB CII/90K). LRT, defined as the current level
yielding an ECAP with zero amplitude, was calculated for both computer- (C-LRT) and human-
picked peaks (H-LRT). VDT, defined as the lowest level resulting in a measurable ECAP
response, was also calculated for both computer- (C-VDT) and human-picked peaks (H-VDT).
Because NRI assigns peak markers to all waveforms but does not include waveforms with
amplitudes less than 20 μV in its regression calculation, C-VDT for AB subjects was defined as
the lowest current level yielding an amplitude ≥20 μV.
Results—Overall, there were significant correlations between human and computer decisions for
peak-marker placement, LRT, and VDT for both manufacturers (r = 0.78 to 1.00, p < 0.001). For
Cochlear devices, LRT and VDT correlated equally well for both computer- and human-picked
peaks (r = 0.98 to 0.99, p < 0.001), which likely reflects the well-defined NRT algorithm and the
lower noise floor in the 24RE and CI512 devices. For AB devices, correlations between LRT and
VDT for both peak-picker methods were weaker than for Cochlear devices (r = 0.69 to 0.85, p <
0.001), which likely reflect the higher noise floor of the system. Disagreement between computer
and human decisions regarding the presence of an ECAP response occurred for 5.0 % of traces for
Cochlear devices and 2.1 % of traces for AB devices.
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Conclusions—Results indicate that human and computer peak-picking methods can be used
with similar accuracy for both Cochlear and AB devices. Either C-VDT or C-LRT can be used
with equal confidence for Cochlear 24RE and CI512 recipients because both methods are strongly
correlated with human decisions. However for AB devices, greater variability exists between
different threshold determination methods. This finding should be considered in the context of
using ECAP measures to assist with programming CIs.
Keywords
cochlear implant; electrically evoked compound action potential; threshold; Neural Response
Telemetry; Neural Response Imaging
INTRODUCTION
Presently, cochlear implant (CI) manufacturers offer devices with telemetry capabilities for
measuring the electrically evoked compound action potential (ECAP). Clinically, ECAP
measures can provide an objective means to verify neural and implant function by recording
the synchronous activity of auditory-nerve fibers in response to electrical stimulation.
ECAPs can also be used to monitor physiology over time, guide speech processor fitting
when behavioral results are difficult to obtain, and assist in managing complicated cases
(e.g., Botros & Psarros, 2010; Franck & Norton, 2001; Han et al., 2005; Holstad et al., 2009;
Hughes et al., 2000). The mechanisms for measurement of ECAP responses, known as
Neural Response Telemetry for Cochlear devices (NRT™; Cochlear Ltd., Macquarie, New
South Wales, Australia) and Neural Response Imaging for Advanced Bionics devices(NRI;
Advanced Bionics [AB], Valencia, California, USA), have been incorporated into the
respective fitting software to allow for use in device programming. These mechanisms
measure ECAP waveforms in response to a range of stimulus levels (i.e., an amplitude
growth function) in order to determine the lowest unit of current where an ECAP response is
present, known as the visual-detection ECAP threshold.
Several methods exist for determining ECAP thresholds. Clinicians can choose to use
thresholds determined by the software or they can use their own judgments in lieu of the
software’s algorithms. When an ECAP response is measured with the clinical software, the
N1 and P2 peaks are automatically picked based on the software’s specific algorithms (Fig.
1). In the Cochlear software, two different mechanisms exist for measuring NRT™: an
automatic mode, AutoNRT™, and a manual mode, Advanced NRT™. In AutoNRT™, the
software starts at a low current level (CL) and increases the level of stimulation until an
ECAP measure meeting the algorithm is obtained. Once this ECAP response is measured,
the level is decreased to better define the threshold level (Botros et al., 2007). Each
waveform is analyzed relative to the waveform collected immediately prior. In Advanced
NRT™, the starting level for the stimulus and masker must be obtained prior to obtaining
ECAP responses, and each waveform is analyzed as an individual trace (A. Botros personal
communication, 2009). For both AutoNRT™ and Advanced NRT™, peaks are picked based
on the AutoNRT™ expert system (described in Botros et al., 2007). In this algorithm, N1 is
defined as the minimum of the first 8 samples and P2 is the maximum of the samples after
N1, up to and including sample 16. When the algorithm is violated, the amplitude of the
ECAP response is recorded as 0 μV and peaks are not marked. Possible algorithm violations
for Nucleus 24RE or CI512 devices include the following: (1) the negative peak is clipped,
(2) the tested electrode is out of voltage compliance, (3) N1 minus P1 is less than 0 μV, (4)
the latency between N1 and P2 is less than 2 samples (~98 μsec), and (5) the latency
between N1 and P2 is greater than 12 samples (~584 μsec). For AB devices, the NRI peak-
picker algorithm uses the first most negative peak value in the range of 270 to 670 μsec and
then the following most positive value in the range of 370 μsec or N1 time + 100 μsec
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(whichever is greater) to 1000 μsec to define N1 and P2. The ECAP waveform must follow
the end of the stimulus plus 5 samples, and the waveform must be at least 61 samples long
(~18 μsec sampling interval; P. Trautwein and K. Hood, personal communications, 2009).
The software will pick peaks if the tested electrode is out of voltage compliance, but
designates those electrodes with a bolded ring around the electrode icon on the software
screen. In the NRI algorithm, peaks are picked for all waveforms, but only waveforms with
peak-to-peak amplitudes of ≥20 μV are included in the regression analysis that is used to
determine ECAP threshold.
Although ECAP N1 and P2 peaks are automatically picked when using the commercial
clinical software, a clinician can choose to adjust the peak markers based on his or her own
experienced judgments. Using this method, a clinician can choose to include waveforms that
violate the software’s algorithm or exclude waveforms that meet the parameters of the
software’s algorithm but appear to be an artifact of the noise floor. Within both computer
and human peak-picking methods, ECAP thresholds can be determined through linear-
regression analysis or by visual detection.
Software-generated thresholds are presently determined using a linear-regression analysis
applied to computer-picked peaks in an amplitude-growth function. These are commonly
referred to as T-NRT (Cochlear) and tNRI (AB); in the present study they are referred to as
computer linear-regression thresholds (C-LRT). With this method, a regression line is
applied to ECAP traces with marked peaks, and threshold is defined as the current level for a
zero-amplitude intercept. The linear-regression method requires at least three suprathreshold
responses at different current levels to calculate a regression line, which may be difficult to
obtain if ECAP thresholds approach the patient’s uncomfortable loudness levels (Hughes,
2010). The method assumes that ECAP response amplitudes increase linearly with increases
in current level; an assumption that may not always be valid (Botros et al., 2007; Lai &
Dillier, 2007). Alternatively, clinicians may use judgments to adjust, add, or delete
computer-based peak markers and use the resulting linear-regression threshold based on
human-picked peaks. For the present study, this latter threshold-determination method is
referred to as human linear-regression threshold (H-LRT).
An alternative method of threshold determination is visual detection. The visual-detection
method is more subjective, where threshold is determined as the lowest current level for
which an ECAP waveform can be visually identified by a human observer. Unlike the linear
regression method which requires multiple responses, the visual detection method utilizes a
single response. This method works best in systems with a low noise floor. For systems with
a high noise floor, ECAP responses occurring at low current levels may be obscured,
resulting in artificially elevated threshold estimates (Hughes, 2010). Although visual
detection is a term that traditionally applies to human decisions, visual-detection thresholds
(VDTs) can be determined from peak markers placed automatically by computer algorithms,
as well as from human-picked peak markers. For this study, these threshold determination
methods are referred to as C-VDT and H-VDT, respectively, where C-VDT is defined as the
lowest level where the computer algorithm picked peaks that were included in the regression
analysis, and H-VDT is defined as the lowest level where a clinician identified an ECAP
response based on human-picked peaks.
To date, only a few studies have assessed the variability between different peak-picker and
threshold-determination methods. For Cochlear devices, Botros et al. (2007) and van Dijk et
al. (2007) compared computer-based VDTs to human-determined VDTs and found less than
9 current-level units (CL1) difference between the two methods in 90% of cases. In a
comparison of VDT and LRT methods, Jeon et al. (2010) found a significant correlation
between VDT and LRT (r = 0.9) in a group of 12 AB CII/90K recipients; however VDTs
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were an average of 23 clinical units (CU2) higher than LRTs. In a group of nine AB CII
recipients, Han et al. (2005) found a stronger correlation between most-comfortable (M)
levels and ECAP thresholds obtained with visual detection (r = 0.741) than with linear
regression (r = 0.675). Similarly, for adult Cochlear recipients, Potts et al. (2007) found
slightly better correlations between comfort (C) levels and ECAP thresholds obtained with
visual detection (r = 0.69) than with linear regression (r = 0.66). In contrast to these findings,
somewhat better correlations were found using linear regression than visual detection for
pediatric Cochlear recipients (Holstad et al., 2009).
If there are large differences among the methods used to determine ECAP thresholds,
clinical interpretations of ECAP responses may be impacted. Automated algorithms are
designed to circumvent the variability in the level of expertise across clinicians. However,
one issue is that clinicians may not document the specific method used to determine ECAP
thresholds in patient reports. The use of different methods among clinicians who follow the
same patient can introduce variability into the patient’s care. In order for clinicians to use
ECAP thresholds to guide programming levels and measure potential changes in physiology
over time, it is important to understand how the use of different peak-picker and threshold-
determination methods affects ECAP threshold measures. The primary goal of this study
was to determine the extent to which ECAP peak markers and thresholds differ for computer
algorithms versus human decisions when the same threshold-determination method is used
(i.e., linear regression or visual detection). A secondary goal was to examine differences in
ECAP thresholds obtained using simple-linear regression analysis versus visual detection.
MATERIALS AND METHODS
Subjects
Three electrodes (one basal, middle, and apical) were tested for each of 20 ears in 20 CI
recipients (17 adults, 3 children). Ten subjects were implanted with Cochlear devices
(Cochlear Ltd., Macquarie, New South Wales, Australia): nine with the Nucleus®
24RE[CA] and one with the Nucleus® CI512). Ten subjects were implanted with AB
devices (Advanced Bionics, Sylmar, California, USA): five with the CII and five with the
HiRes 90K. Subjects were recruited as they were seen for other studies in our laboratory,
and had to be at least 11 years old with a minimum of 3 months of device use. Demographic
and test-electrode information for participants is provided in Table 1. One Cochlear subject,
F10, was originally implanted with an AB HiRes 90K, which was explanted due to device
failure after 3 years of use. The subject was reimplanted with a Nucleus 24RE, which was
the device tested in this study. For this subject, the age at first implant and total duration of
device use is listed in Table 1, with the age at reimplant and duration of 24RE device use
listed in parentheses.
Electrode impedance was measured prior to data collection using the clinical-programming
software (Custom Sound™ EP for Cochlear and SoundWave™ for AB). Electrodes
categorized as short or open circuits as determined by the manufacturer’s clinical software
were excluded from testing. Amplitude growth functions were generally obtained for
electrodes 3, 11, and 20 for Cochlear subjects and electrodes 1, 8, and 14 for AB subjects.
Deviations from this set were necessary only when electrode impedance was outside the
normal range (Subject C19), electrodes were deactivated (Subject C21), or measurable
ECAPs could not be recorded (Subject F2). For these subjects, the closest electrode with a
1CL is a log-based current unit used with Cochlear devices, where current (in microamperes) equals 17.5*100(CL/255) for Nucleus
24RE or CI512 devices (Botros et al. 2007).
2CU is a linear charge unit used with AB devices, where current (in microamperes) equals CU/(PW*0.013). The default pulse width
(PW) in NRI is 32 microseconds (P. Chellakumar, personal communication, 2010).
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measurable ECAP response within the same region (basal, middle, or apical) was tested. For
subject C20, ECAPs could not be obtained for any basal electrode (electrodes 12-16; see
Table 1). The total number of amplitude growth functions obtained for each device was 30
for Cochlear subjects, and 29 for AB subjects.
ECAP Measures
Cochlear—ECAP thresholds were obtained using the Advanced NRT feature within
Custom Sound™ EP (version 2.0.4.7298)3. Stimuli were delivered through a laboratory
Freedom speech processor interfaced with a programming pod. Prior to data collection, an
ascending procedure was used to estimate behavioral threshold and upper comfort levels for
the stimulus used to elicit ECAPs. The masker and probe were set to equal current levels (as
described in Abbas et al., 1999) and were increased in steps of 5 CL. The subject was
instructed to indicate when the sound was first heard and when the sound was loud but not
uncomfortable. These judgments corresponded to ratings of 1 and 8, respectively, on a
visual scale of 0–10, where 0 was no sound and 10 was too loud. For ECAP recordings, the
masker level was fixed at the current level corresponding to a loudness rating of 8, while the
probe level was decreased in 5-CL increments until no response could be visually identified.
Additional waveforms were collected in 2-3 CL steps near threshold. The standard forward-
masking paradigm (A-B+C-D) was used for artifact reduction (e.g., Abbas et al., 1999,
Brown et al., 1998, Dillier et al., 2002).
Recordings were made using the default parameters in the Custom Sound™ EP software
(recording electrode located two positions apical to the stimulating electrode). All
waveforms were collected at a probe rate of 80 Hz with the masker-probe interval fixed at
400 μsec. The default gain was 50 dB, with 50 sweeps, and the default sampling delay was
122 μsec, which was optimized individually as needed. A default pulse width of 25 μsec/
phase was used for both devices except when voltage-compliance limits were reached. This
occurred for subject F1, so the pulse width was increased to 50 μsec to remain within
voltage-compliance limits. Recording parameters for all Cochlear subjects were adjusted
individually to optimize the ECAP waveform and minimize stimulus artifact (following
Abbas et al., 1999). This was typically accomplished by adjusting only the sampling delay.
Because the internal chip is the same for 24RE and CI512 devices, both Cochlear device
types were analyzed together.
AB—ECAP thresholds were obtained using the NRI feature within SoundWave™ (version
1.4.77). Stimuli were delivered through a laboratory Platinum Series speech processor
interfaced with a clinical programming interface (CPI II). ECAPs were obtained using
ascending current levels with alternating polarity for artifact reduction (e.g., Miller et al.,
1998). The initial stimulation level was set to 50 CU, as this was typically not audible.
Current was increased in 15-CU increments until the subject reported that the stimulus
reached maximum comfort levels or an ending level of 399 CU was reached, whichever
came first. A final level of 399 CU was chosen because it typically remained within voltage-
compliance limits and was tolerable by most subjects. ECAP recordings were made using
the default parameters of the SoundWave™ software (recording electrode two positions
apical to the stimulating electrode). All traces were collected using a cathodic-first sequence
with ADC gain of 300 (linear multiplier). ECAPs for both CII and 90K devices were
collected using 128 averages with a pulse width of 32 μsec/phase and a pulse rate of 30 pps.
Because the internal chip is the same for CII and HiRes 90K devices, both AB device types
were analyzed together. NRI does not allow for the user to adjust many of the measurement
3The Advanced NRT mode was used because it allowed for an analysis of each waveform of the amplitude growth function rather
than the threshold alone.
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parameters, so if a response could not be obtained by changing the recording electrode, an
adjacent stimulating electrode was substituted.
ECAP measures were obtained differently for each manufacturer due to inherent differences
between Cochlear and AB software. Cochlear software utilizes forward masking for
stimulus artifact reduction. For this method, the masker is fixed at a high level, with
amplitude growth functions collected for a descending probe level. Therefore, a loud-but-
comfortable starting level had to be obtained using ascending loudness-growth measures for
Cochlear subjects prior to ECAP measurements in order to avoid overstimulation. Because
AB software only utilizes alternating polarity for artifact reduction, ECAP measurements
were obtained in an ascending fashion while simultaneously monitoring loudness growth,
similar to the initial loudness measures made for Cochlear subjects. Software usability also
affected the method in which ECAPs were obtained for each device. For Cochlear subjects,
additional waveforms could easily be added into the existing growth function and
incorporated into the LRT function. This capability was not available in the AB
SoundWave™ software used for this study. Finally, the difference in current units between
manufacturers accounts for the differences in step sizes used for the present study. Cochlear
uses log-based CL and AB uses linear units of current (CU). The step size for AB was fixed
at 15 CU for the entire growth function, whereas the step size for Cochlear was 5 CL with
steps of 2-3 CL near threshold. Because CL is log-based, the equivalent current-unit step
size for 2-3 CL varies depending upon the specific value in CL.
Computer Analysis
For the computer-determined measurements (C-LRT and C-VDT), N1 and P2 latencies and
peak-to-peak amplitudes were determined for each trace based on the software-specific
peak-picker algorithms described in the Introduction. In this phase of the data analysis, there
was no human intervention to adjust the peak markers. ECAP thresholds were determined
using linear regression and C-VDT (i.e., the lowest level where the computer algorithm
identified an ECAP). Simple linear regression was applied to the computer-marked peaks by
the automated software algorithms. The linear-regression threshold (C-LRT) was defined by
the software algorithms as the current level for a zero-amplitude intercept of the extrapolated
regression line. Figure 1 shows screen shots of amplitude growth functions for a Cochlear
(top) and an AB (bottom) recipient. For the Cochlear recipient, the Advanced NRT
algorithm picked peaks for the waveforms corresponding to 215 CL down to 170 CL
(cascade pane on the left), and plotted those peak-to-peak amplitudes in the analysis pane
(middle panel on the right). The C-LRT (“intersection”; also called extrapolated T-NRT in
the software) was 168.6 CL in this case. For the AB recipient (Fig. 1, bottom), the NRI
algorithm picked peaks for all waveforms, and plotted those peak-to-peak amplitudes in the
graph on the right. The C-LRT (called tNRI in the software) was 129 CU in this example. It
is important to note that in the AB software, peaks are picked for amplitudes <20 μV, but
those amplitudes are not included in the regression analysis by the algorithm (P. Trautwein
personal communication, 2009). Data points that are included in the regression analysis are
represented by filled circles, whereas data points not included in the analysis are represented
by open circles (the gray circle simply indicates which waveform is highlighted in the left
column).
Due to differences in the software peak-picker algorithms, visual-detection thresholds were
defined differently between manufacturers. For Cochlear subjects, visual-detection threshold
(C-VDT) was defined as the lowest current level where the computer’s algorithm picked
peaks. The C-VDT was 170 CL for the Cochlear recipient in Fig. 1 (top). Because the AB
NRI algorithm does not include ECAP amplitudes <20 μV in its regression calculation, C-
VDT for AB subjects was defined as the lowest current level yielding an amplitude of at
least 20 μV that was included in the linear-regression analysis. For the AB recipient in Fig.
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1 (bottom), the C-VDT was 195 CU (second waveform highlighted in the cascade pane on
the left). The ECAP amplitude at 195 CU was 22 μV, whereas the ECAP amplitude for the
next lowest stimulus level of 181 CU was 17 μV, which was not included in the regression
analysis (top waveform in the cascade pane on the left).
Human Analysis
Two expert clinicians (one was the second author) with 18 years of combined experience
working with ECAPs (13 years and 5 years, respectively) examined 1142 ECAP waveforms
from 59 electrodes. Once the computer-picked data were stored for separate analysis, peak
markers were removed by the first author so that the two clinicians were blinded to
threshold, slope, latency, and amplitude data initially determined by the software algorithms.
In NRT, peak markers can be manually removed and added. In NRI, peak markers cannot be
removed. Therefore, peak markers in the NRI data were manually set to yield peak-to-peak
amplitudes of zero, with no regard to latency. Each clinician classified waveforms as
“response present” or “response absent” using (1) subjective judgments of the signal-to-
noise ratio, (2) overall waveform shape, and (3) peak latencies relative to other traces within
the growth function to decide whether identifiable peaks were present in the waveform.
Using the method specified by Botros et al. (2007), measurements classified differently by
the two clinicians (i.e., present or absent) were disregarded (5.3%). For measurements
determined to have an ECAP response, clinicians manually marked N1 and P2 peaks. For
measurements determined to have no ECAP response, peak markers were not assigned
(Cochlear software) or were adjusted so that peak-to-peak amplitude was zero (AB
software).
In order to further examine differences between computer and human peak-picking methods,
waveforms judged as no response by either the computer or the clinician were assigned
latency values of zero. The reason for this was twofold: (1) the SoundWave™ software does
not allow for peak markers to be manually removed, (2) in the Custom Sound™ software,
when peaks are left unmarked the amplitude of the ECAP response is recorded as 0 μV with
no assigned value for N1 and P2 latency measures. Therefore, in order to determine how
often a disagreement existed between the computer and clinicians regarding the presence of
an ECAP response, zeros were used as a method for indicating a “response absent”
waveform for both manufacturers. Zero data points were used only for latency and
amplitude measures as these data were obtained from individual waveforms while threshold
data reflected a single data point obtained from each entire amplitude growth function.
ECAP thresholds were determined using linear regression and visual detection. Simple
linear regression was applied to clinician-picked peaks, and the slope of the line and
threshold were calculated as for the computer analysis (H-LRT). Visual-detection threshold
(H-VDT) was defined as the lowest current level where each clinician marked N1 and P2
peaks. The inter-judge reliability revealed strong agreement between the two expert
clinicians regarding the presence of an ECAP response (94.7%). Therefore for all “response
present” measures, the values for N1 and P2 latency, peak-to-peak amplitude, and threshold
were averaged across clinicians for comparison with those determined by the software
algorithms. Correlations calculated between clinicians were significant across all measures
(r = 0.88 to 1.00, p < 0.001).
RESULTS
Computer vs. Human: Peak Markers
The first goal of this study was to assess the variability between human and computer
decisions for marking ECAP N1 and P2 peaks, and compare linear regression and visual
detection methods within and across human and computer threshold determination methods.
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In Figure 2, computer- versus human-picked peaks were compared for N1 latency (Figs. 2A-
B), P2 latency (Figs. 2C-D), and peak-to-peak amplitude (Figs. 2E-F). Figures in the left
column (2A, 2C, and 2E) correspond to Cochlear data and figures in the right column (2B,
2D, and 2F) correspond to AB data. Pearson correlation coefficients were calculated using
SigmaStat 3.0 (SPSS Inc., Chicago, IL) for each comparison. Data points included in Figure
2 correspond to waveforms where both computer and human peak-picking methods agreed
on the presence of an ECAP response (i.e., without zero data points). The solid black line
within each panel of Figure 2 represents the linear regression analysis without the zero data
points for Cochlear and AB devices, and the dashed line represents unity. For N1 latency
and peak-to-peak amplitude measures, data occurred on both sides of the unity line (i.e.,
unbiased). For P2 measures, latencies for computer-picked peaks tended to be longer than
those for human-picked peaks, particularly for Cochlear devices (Fig. 2C). This may be a
result of clinicians picking the P2 peak at the beginning of the plateau, while the software
algorithm looks for a latency that falls within a specified time window. A second set of
correlations was calculated for all measured traces, including those containing zero data
points (indicating disagreement between human and computer regarding the presence of a
response). Both sets of correlations (with and without zero data points) are reported in Table
2. For these calculations, traces with amplitudes <20 μV were included for AB subjects if
the clinicians determined a present ECAP response, but were otherwise excluded because
traces with amplitudes <20 μV are not included in NRI linear regression calculations. The
mean differences between human- and computer-picked peaks for each device type in Fig.2
are provided in the first three rows of Table 3. Because differences for individual subjects
may be positive (the value for computer-picked peaks is greater than the value for human-
picked peaks) while others may be negative (the value for computer-picked peaks is less
than the value for human-picked peaks), differences averaged across all subjects were
calculated using absolute values. The mean difference between computer- and human-
picked peaks was similar between Cochlear and AB devices for N1 latency (2.65 μsec for
Cochlear; 5.61 μsec for AB) and amplitude measures (1.04 μV for Cochlear; 1.10 μV for
AB), but showed more variability for P2 latencies (34.33 μsec for Cochlear; 17.29 μsec for
AB).
Regarding the waveforms for which human and computer decisions agreed on the presence/
absence of an ECAP response, Figures 2A and B show significant correlations (r = 0.98 for
both device groups) between the expert clinicians and software algorithms for N1 peak
latency (Table 2). Figures 2C and D show significant correlations (r = 0.78 for Cochlear; and
r =0.95 for AB) between the expert clinicians and software algorithms for P2 latency.
Figures 2E and F show significant correlations(r =1.0 for both device groups) between the
expert clinicians and software algorithms for peak-to-peak amplitude.
Regarding the waveforms for which human and computer decisions did not agree on the
presence/absence of an ECAP response, correlations were still significant, but not as strong,
particularly for the AB device group (Table 2, with zero data points). An example of
disagreement between computer and human decisions in AB subjects is shown in Figure 3.
Figure 3 shows an example of computer-picked peaks in NRI (top) and human-picked peaks
on the same data set (bottom). In the top panel, the software algorithm marked a peak
(indicated as the gray bolded circle) that clinicians identified as artifact within the noise
floor of the recording system (open bolded circle set to zero in the bottom panel). The gray
highlighted peak marked in the top panel corresponds to the trace at 152 CU, which has an
amplitude of 21 μV and therefore was included in the computer linear-regression analysis.
Traces at 166, 181, 195, and 210 CU, however, were not included in the LRT analysis
because the amplitudes are <20 μV and therefore did not meet inclusion criteria. In Fig. 3,
C-LRT was 145 CU for the computer-picked peaks (top), and H-LRT was 163 for human-
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picked peaks (bottom). Therefore, the inclusion of this one peak in the C-LRT calculation
accounts for the large variability between the C-LRT and the H-LRT in this example.
Computer vs. Human: Linear-Regression Thresholds
With the linear-regression method, the regression line can be defined by its slope, and
threshold is determined as the x-intercept. For slope, results for both device groups show
significant correlations (r >0.99). Correlation coefficients and p values for each
manufacturer are reported in Table 4. Figures 4A and B show H-LRTs versus C-LRTs for
Cochlear (panel A) and AB subjects (panel B). Results for both device groups show
significant correlations (r > 0.99 for Cochlear; r = 0.99 for AB). Data points were unbiased
for both Cochlear and AB devices. Mean differences in both clinical units of measure (CL or
CU) and current (μA) are reported in Table 3 for both device groups. For clinical units of
measure, mean absolute-value differences were 1.10 CL for Cochlear, and 3.61 CU for AB,
which corresponded to mean differences in current of 6.18 μA for Cochlear, and 8.67 μA
for AB. On average, the C-LRT was lower than the H-LRT for both devices.
It is important to note that Cochlear and AB devices use different units of measurement for
stimulus level (CL and CU, respectively). Because one is logarithmic based (CL) and the
other is linear (CU), it is not appropriate to compare correlation coefficients between devices
for threshold or slope data. If one wanted to make such a comparison, the data for both
devices should be converted to current, in which case the correlation coefficients would
change (more so for the log-based CL data). While the primary focus of this study was to
compare methods of threshold determination within a device type, mean differences and
standard deviations in both the stimulus-level units specific to each device and current (μA)
are provided in Table 3. This issue is addressed further in the Discussion.
Computer vs. Human: Visual-Detection Thresholds
A common alternative to using C-LRTs (commercially referred to as T-NRT and tNRI) is to
visually determine the lowest current level that yields a measurable response (H-VDT). This
may not be the same level where the computer picked its lowest current level with a
measurable amplitude (C-VDT). Figure 5 shows a comparison of VDTs for human (H-VDT)
and computer (C-VDT) peak-picking methods for Cochlear (panel A), and AB (panel B)
devices. For Cochlear subjects, C-VDT was defined as the lowest current level where the
computer’s algorithm picked peaks. Because the AB algorithm does not include ECAP
amplitudes <20 μV (for LRT), visual-detection threshold for AB subjects was defined as the
lowest current level yielding an amplitude of ≥20 μV. Results for both groups showed
significant correlations between human and computer VDTs (r = 0.98 for Cochlear; r = 0.89
for AB; see Table 4). While data for Cochlear devices were generally unbiased, data from
AB devices revealed C-VDTs that were similar to or less than H-VDTs. For clinical units of
measure, mean absolute-value differences were 3.25 CL for Cochlear and 10.64 CU for AB,
which correspond to mean differences in current of 18.41 μA for Cochlear and 25.58 μA for
AB (Table 3). On average, the H-VDT was slightly higher than C-VDT for both devices.
Visual Detection vs. Linear Regression
In order to examine differences that may exist between visual-detection and linear-
regression methods, a comparison between VDTs and LRTs was made within each peak-
picking method (computer and human). Figure 6 shows a comparison between C-VDTs and
C-LRTs for Cochlear (panel A), and AB (panel B) subjects. Results for both device groups,
provided in Table 4, show significant correlations (r =0.98 for Cochlear; r =0.85 for AB). H-
VDTs and H-LRTs were compared in Figures 6C (Cochlear) and 6D (AB). Results for both
device groups show significant correlations (r =0.99 for Cochlear; r = 0.69 for AB). For
Cochlear devices, data points appeared unbiased for both computer- and human-picked
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peaks (Figs. 6A and 6C, respectively). For AB devices, data obtained for computer-picked
peaks revealed larger C-VDTs than C-LRTs (Fig. 6B), while data for human-picked peaks
(Fig. 6D) showed a greater difference between LRT and VDT than seen for computer-
picked peaks. On average there were only slight differences seen between LRT and VDT
measures for the Cochlear devices: 4.29 CL (23.36 μA) for computer-picked peaks and 2.68
CL (14.38 μA) for human-picked peaks (see Table 3). Mean differences were greater for AB
devices, with an average difference of 23.10 CU (55.54 μA) for computer-picked peaks and
28.54 CU (68.60 μA) for human-picked peaks. For Cochlear subjects, VDT measures
occurred at slightly lower levels than LRT measures, while for AB subjects, VDT measures
occurred at higher levels than LRT, as would be expected based on the definition of each
measure.
Computer vs. Human: Visual Detection vs. Linear Regression
While visual detection and linear regression can be used with both human and computer
peak-picking methods, it may be the case that an inexperienced clinician would use C-LRT,
as it requires the least amount of human judgment of the four methods. Likewise, a seasoned
clinician who picks peaks based on experienced judgments might elect to define threshold as
the lowest level where they can visually detect a response. There would be value in knowing
the extent to which the computer-based threshold determinations agreed with those based on
visual determination by an experienced human observer. Therefore, visual-detection
thresholds using human-picked peaks (H-VDT) were compared with linear-regression
analysis of computer-picked peaks (C-LRT). This comparison essentially represents “fully
computer” versus “fully human” decisions. Figures 7A-B show a comparison of human
VDTs and the computer LRTs obtained with NRT (Cochlear) and NRI (AB), respectively.
Results for both device groups, provided in Table 4, showed significant correlations (r =
0.99 Cochlear 24RE; r = 0.71 for AB). Data obtained for Cochlear devices appeared
unbiased. For AB devices, H-VDT data was almost always higher than that obtained for C-
LRT. Mean absolute-value differences between C-LRT and H-VDT were 2.70 CL (14.97
μA) for Cochlear, and 29.57 CU (71.09 μA) for AB (see Table 3). For both devices, the C-
LRT was lower on average than the H-VDT.
DISCUSSION
The primary goal of this study was to determine the extent to which ECAP peak markers
and thresholds differ for software algorithms versus human decisions when utilizing linear
regression or visual-detection threshold-determination methods. To evaluate these
differences, N1 and P2 peaks and ECAP thresholds determined by AB SoundWave™ and
Cochlear Ltd. Custom Sound™ EP software algorithms were compared to those determined
by two expert clinicians.
Computer vs. Human: Peak Markers
Significant correlations were found between human and computer-picked peaks for N1 and
P2 peak latencies and peak-to-peak amplitudes for Cochlear and AB devices (see Fig. 2)
both with and without the zero points included in the calculations (Table 2). Results of this
analysis revealed low levels of disagreement between human and computer peak-picking
methods for both Cochlear and AB devices. Disagreements between human and computer
decisions regarding the presence/absence of an ECAP occurred for 5.0% of Cochlear traces,
and 2.1% of Advanced Bionics traces. The reason for the large difference between the
correlations calculated with the zero data points and without the zero data points varied
between the two device groups. For both device types, instances where the computer
determined an ECAP response to be present but clinicians did not only occurred when the
software peak-picker algorithm marked peaks for traces that clinicians identified as artifact
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within the noise floor of the recording system. Such instances occurred for 32.0% of the
disagreements (1.6% of measured waveforms) for Cochlear subjects. For AB subjects, the
NRI algorithm in the SoundWave™ software picks peaks for every waveform; therefore
instances where the computer picked traces but the clinician did not accounted for 100% of
the disagreements. However, when computer-picked peaks with amplitudes <20 μV were
excluded from the AB data (because they are not included in AB LRT calculations) the same
instance only accounted for 69% of disagreements (1.45% of measured waveforms).
Instances where the clinicians determined an ECAP response to be present but the computer
did not occurred for 68.0% of instances of disagreement (3.4% of measured waveforms) for
Cochlear subjects; and 31% (0.65% of measured waveforms) for AB subjects. The reason
for this type of disagreement was similar between manufacturers. For both Cochlear and AB
subjects, this generally occurred for waveforms in the lower portion of the growth function
where the peak-to-peak amplitude of the waveform reached low levels. For Cochlear
devices, 88.0% of these instances occurred when the amplitude was <20 μV, with the other
12.0% occurring for waveforms with an amplitude between 20 and 30 μV. For AB subjects,
100.0% of these instances occurred for waveforms where the amplitude was <20 μV;
therefore, as defined by the NRI algorithm, these waveforms were not included in the
regression analysis for C-LRT. For both device types, expert clinicians were able to measure
responses at levels lower than 20 μV, and these waveforms were therefore included in the
regression analysis for H-LRT. The overall disagreement for AB subjects (2.1 %)
corresponds to instances where the amplitude of the response was at least 20 μV, or
instances where the clinicians measured a response below 20 μV.
Computer vs. Human: Linear Regression and Visual Detection
For the linear-regression method, comparisons of slope and threshold showed significant
correlations between human and computer decisions for Cochlear and AB subjects (r = 0.99
to >0.99; Table 4, Fig. 4). For slope, correlation coefficients (Table 4) were strong (r > 0.99
for both device groups) and mean absolute-value differences (Table 3) were small (0.34μV/
CL for Cochlear; and 0.02 μV/CU for AB) for all both device groups. In general, the unit of
measure used yielded small values for slope for most subjects.
For LRTs, significant correlations were found when comparing human and computer peak-
picking methods for both device groups. Likewise, mean absolute-value differences were
small for both manufacturers. This suggests that human and computer peak-picking methods
can be used with similar reliability for Cochlear and AB devices if LRT is used.
For VDTs, a comparison of human and computer peak-picking methods showed significant
correlations for both device groups(r = 0.89 to 0.98; Table 4, Fig. 5). This means that the
lowest current level where the computer’s algorithm identified a measurable ECAP was
generally consistent with that of the clinician using visual detection with human-picked
peaks. Although NRI marks peaks on all waveforms (AB devices), we applied the
algorithm’s rule for LRT to define C-VDT as the lowest current level that was included in
the linear-regression analysis. This generally agreed with H-VDT, and suggests that ECAPs
are typically not visually identifiable below approximately 20 μV in the AB system. For
Cochlear users, Botros et al. (2007) and van Dijk et al. (2007) reported less than 9 CL
difference between C-VDT and H-VDT in 90% of cases. A similar comparison is shown in
Fig. 5A, where the average (absolute-value) difference between C-VDT and H-VDT for
Cochlear subjects was 3.25 CL (range: 0-13 CL; Table 3). There was less than 9 CL
difference in 90% of cases for Cochlear devices, which is consistent with that reported by
Botros et al. (2007) and van Dijk et al. (2007). For AB data (Fig. 5B), the average difference
between C-VDT and H-VDT was 10.64 CU (range: 0-66 CU). Again, note that the
correlation coefficients calculated using clinical units of measure cannot be compared across
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devices due to differences in the current-level units used (log-based CL versus linear CU). In
order to allow for some comparison between devices, clinical units of measure were
converted to current in Table 3. In current (μA), mean differences were 18.41 μA (range:
0-82 μA) for Cochlear users, and 25.58 μA (range: 0-158 μA) for AB users. These
differences indicate that for some recipients, particularly those with AB devices, greater
variability may exist between computer- and human-peak picking methods.
For Cochlear data, there was a significant correlation between LRT and VDT for both
computer and human-picked peaks (Fig. 6A and C). On average, there were only slight
differences between LRT and VDT measures for computer- and human-picked peaks (4.29
CL and 2.68 CL, respectively; Table 3), and VDT was generally lower than LRT for both
computer and human decisions. The correlation between LRT and VDT for human-picked
peaks (Fig. 6C) was only slightly stronger than for computer-picked peaks for Cochlear
subjects (Fig. 6A).
The consistent results for computer and human decisions for Cochlear devices was likely
due to a combination of the well-defined NRT algorithm, which is based on correlations
with a large bank of template waveforms (Botros et al., 2007; Van Dijk et al., 2007), as well
as the relatively low noise floor for the 24RE and CI512 devices. The noise floor is
approximately 2-5 μV for both the Nucleus 24RE and the Nucleus CI512 (Holstad et al.,
2009; Patrick et al., 2006; Van Dijk et al., 2007.)
For AB data, the correlation between LRT and VDT was poorer for human-picked peaks
(Fig. 6D) than for computer-picked peaks (Fig. 6B). On average, differences between VDT
and LRT (absolute value) were 23.1 CU and 28.54 CU for computer and human decisions,
respectively (Table 3), and VDT was generally higher than LRT for both human and
computer decisions. These results are consistent with those reported by Jeon et al. (2010),
who found that VDTs were an average of 23 clinical units (CU) higher than LRTs in a group
of 12 AB CII/90K recipients. For computer-picked peaks, the linear-regression function in
NRI includes peaks down to 20 μV, and VDT was defined as the lowest level yielding an
ECAP amplitude of at least 20 μV. Thus, the decision rules were similar for both C-LRT
and C-VDT, leading to good agreement between the two measures. For human-picked
peaks, while the correlations were still significant, the decision rules applied to LRT and
VDT differed more. In general, VDTs are typically higher than LRTs because of the
decision rules associated with each method. Linear regression estimates threshold as the
current level for an ECAP amplitude of 0 μV, whereas visual detection requires a
measurable ECAP response, which by definition, must be greater than 0 μV. In systems
with low noise floors, VDT will more closely approximate LRT, while in systems with high
noise floors, there will be more variability. For example, in subjects with noisier responses,
the H-VDT may not be visible until the growth function reaches an amplitude much larger
than 20 uV, since by definition the H-VDT can only be seen above the noise floor (in NRI,
the noise floor is roughly 20-50 μV). In contrast, the C-VDT could theoretically occur
within the noise floor, as by definition it only requires the waveform to be included in the
linear regression calculation and may or may not correspond to a visible/measurable
response. Further, a non-linear growth function can yield a lower LRT than VDT, as it is not
restricted by the noise floor. These differences will be accentuated in systems with a
relatively high noise floor, where VDT is less accurate.
Perhaps the most clinically applicable comparison is shown in Fig. 7. Those data represent a
comparison between strictly automated and strictly human decisions. Inexperienced
clinicians may be inclined to rely on computer-picked peaks and LRT, whereas expert
clinicians may be inclined to use years of clinical experience to override computer-based
peak markers and identify threshold based on visual detection. One disadvantage of the
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linear-regression method is that there must be at least three suprathreshold ECAP measures
in the amplitude growth function for a regression analysis to be performed. This can be
challenging in cases where the ECAP threshold occurs near the recipient’s upper loudness
tolerance levels (i.e., Hughes, 2010). Further, regression analysis assumes that the function
is linear, which in many cases it is not (i.e., Botros et al., 2007). Because of these
limitations, VDT is an attractive alternative, particularly in systems with a low noise floor.
If we propose that H-VDT determined by experienced clinicians represents the gold
standard, then a comparison of Figs. 5 and 7 within each device can provide useful
information regarding the reliability/validity of C-VDT and C-LRT. For Cochlear devices,
the correlation coefficients were nearly identical for H-VDT versus C-VDT (Fig. 5A) and
H-VDT versus C-LRT (Fig. 7A). This suggests that either C-VDT or C-LRT can be used
with equal confidence for Cochlear 24RE and CI512 recipients, and that both methods are
significantly correlated with expert human decisions. This finding is in agreement with data
from Potts et al. (2007), who reported only slightly better correlations between C-levels and
ECAP thresholds obtained with visual detection (r = 0.69) than with linear regression (r =
0.66) in a group of adult Cochlear recipients.
For AB devices, while the correlations were significant, the correlation between H-VDT and
C-VDT was stronger (r = 0.89 for AB; Fig. 5B) than for H-VDT versus C-LRT (r = 0.71 for
AB; Fig. 7B). This suggests that the linear-regression method for AB recipients (i.e., tNRI)
is less accurate when compared with expert human decisions.
The comparison between Figs. 5 and 7 shows that the utility of the linear-regression method
differs between devices. This is because both manufacturers employ the same analysis
(linear regression) on different units of measure for current. For Cochlear data, linear
regression is performed on a linear-logarithmic growth function, where ECAP amplitude is a
linear unit of measure and current level is logarithmic. In contrast, regression for AB data is
performed on a linear-linear function, where both ECAP amplitude and current unit are
linear measures. Further, linear-regression analysis assumes that ECAP amplitudes increase
linearly with current, which is not always the case (Botros et al., 2007, Lai & Dillier, 2007).
On a linear scale, ECAP growth functions seen physiologically tend to be sigmoidal (Miller
et al., 2000). This can also happen on a logarithmic scale, which may account for the plateau
illustrated in the Cochlear screen capture shown in Fig. 1. In this example, the trace in the
middle right-hand panel shows a plateau at 210 and 215 CL. Because these points are
included in the linear regression analysis, the slope of the linear regression line is reduced,
and the t-NRT (C-LRT) occurs at a lower level than if these points were not included. The
plateau in Fig. 1 may have alternatively been caused by saturation of the current source,
which would cause a similar effect.
In our clinical observations, it is also not uncommon to see ECAP growth functions with
slow growth of amplitude at low levels (“T-tails”) in Cochlear recipients, and plateaus at
high levels in AB recipients. A log-based measure of current will accentuate the slow-
growth portion of the function, making an exponential regression more appropriate than a
linear regression, as proposed by Lai and Dillier (2007) for Cochlear users. Although LRT
measures correlate well with VDT for most subjects in the present study, in some cases
greater variability between these measures could lead to inconsistent applications of ECAP
measures for these patients. For example, in Cochlear recipients, a log-based measure of
current will de-emphasize plateaus at high levels causing LRT to be overestimated in
comparison with VDT. The opposite is true in the case of AB recipients: a linear measure of
current will de-emphasize the slow-growth portion at low levels, and emphasize the plateau
at high levels causing LRT to occur at a much lower level than VDT. In some instances, the
software algorithm may even return negative values for tNRI (C-LRT), and by definition, a
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threshold cannot be negative. In any case, it appears that linear regression may not be the
most appropriate analysis for automated estimation of ECAP thresholds, regardless of
whether linear or logarithmic current measures are used. Thus, it is important to consider
(and document) the method used to determine ECAP thresholds when those measures are to
be used clinically to assist in creating speech-processor programs or documenting potential
changes over time.
Clinically, the relationship between linear regression and visual detection methods of
threshold determination will likely affect the accuracy with which ECAP thresholds can be
used to assist in the mapping process. For example, Han et al. (2005) found a stronger
correlation between comfort (M) levels and ECAP thresholds obtained with visual detection
(r = 0.74) than with linear regression (r = 0.68) in a group of nine AB CII recipients. For
Cochlear devices, a study by Potts et al. (2007) found slightly better correlations between
comfort (C) levels and ECAP thresholds obtained with visual detection (r = 0.69) than with
linear regression (r = 0.66). While it was not the goal of the present study to compare ECAP
threshold determination methods to behavioral map levels (map stimulation rates were not
prospectively controlled), it would be a relevant topic for further study.
In conclusion, the results from this study showed significant correlations between computer
and expert human decisions within LRT and VDT methods for both Cochlear and AB
devices. For Cochlear data, LRT and VDT correlated equally well for both computer-picked
and human-picked peaks, which likely reflects the well-defined NRT algorithm and the
lower noise floor in the 24RE and CI512 devices. For AB data, the correlation between LRT
and VDT was poorer for human-picked peaks than for computer-picked peaks, which is
likely due to a combination of differences in the decision rules applied to each method and
the higher noise floor of the system.
Finally, for both device groups, the four ECAP threshold determination methods showed
significant correlations; therefore clinicians can use any of the four methods to assist in
setting map levels. For Cochlear recipients, either C-LRT (ie., T-NRT) or C-VDT can be
used with equal confidence because both methods are strongly correlated with expert human
decisions. However for AB devices, C-LRT (i.e., tNRI) introduces more variability when
compared with expert human decisions. Therefore, it is important for clinicians to be aware
of the threshold determination method used in order to ensure consistency in programming
and document potential changes over time. This finding should be considered in the context
of using ECAP measures to program processors for CI recipients.
Acknowledgments
This research was supported by the NIH, NIDCD R01 DC009595, P30 DC04662, and T35 DC008757. The content
of this project is solely the responsibility of the authors and does not necessarily represent the official views of the
NIH or the NIDCD. The authors thank Lisa Stille (BTNRH) for assistance with data analysis; Jenny Goehring and
Jacquelyn Baudhuin (BTNRH) for assistance with data collection; Praveen Chellakumar at Advanced Bionics for
technical support with data extraction from the SoundWave™ clinical software; Andrew Botros at Cochlear Ltd.
for technical expertise regarding NRT algorithms; and Michael Gorga and three anonymous reviewers for helpful
comments on earlier versions of this manuscript.
References
Abbas PJ, Brown CJ, Shallop JK, et al. Summary of results using the Nucleus CI24M implant to
record the electrically evoked compound action potential. Ear and Hearing. 1999; 20:45–59.
[PubMed: 10037065]
Botros A, van Dijk B, Killian M. AutoNRT™: An automated system that measures ECAP thresholds
with the Nucleus Freedom™ cochlear implant via machine intelligence. Artificial Intelligence in
Medicine. 2007; 40:15–28. [PubMed: 16920343]
Glassman and Hughes Page 14










Botros A, Psarros C. Neural Response Telemetry reconsidered: I. The relevance of ECAP threshold
profiles and scaled profiles to cochlear implant fitting. Ear and Hearing. 2010; 31:367–379.
[PubMed: 20124902]
Brown CJ, Abbas PJ, Gantz B. Preliminary experience with Neural Response Telemetry in the
Nucleus CI24m cochlear implant. American Journal of Otology. 1998; 19:320–327. [PubMed:
9596182]
Dillier N, Lai WK, Almqvist B, et al. Meaurement of the electrically evoked compound action
potential via a neural response telemetry system. Annals of Otology, Rhinology & Laryngology.
2002; 111(5):407–414.
Franck KH, Norton SJ. Estimation of psychophyical levels using the electrically evoked compound
action potential measured with the neural response telemetry capabilities of Cochlear Corporation’s
CI24M device. Ear and Hearing. 2001; 22:289–299. [PubMed: 11527036]
Han D-M, Chen X-Q, Zhao X-T, et al. Comparisons between Neural Response Imaging thresholds,
electrically evoked auditory reflex thresholds and most comfortable loudness levels in CII Bionic
Ear users with HiResolution sound processing strategies. Acta Oto-Laryngologica. 2005; 125:732–
735. [PubMed: 16012035]
Holstad B, Sonneveldt VG, Fears BT, et al. Relation of electrically evoked compound action potential
thresholds to behavioral T- and C-levels in children with cochlear implants. Ear and Hearing. 2009;
30:115–127. [PubMed: 19125034]
Hughes, ML. Fundamentals of clinical ECAP measures in cochlear implants: Part 1: Use of the ECAP
in speech processor programming. Audiology Online. 22010 Nov 8. Article 2347. Retrieved
November 8, 2010 from http://www.audiologyonline.com/articles/article_detail.asp?
article_id=2347
Hughes ML, Brown CJ, Abbas PJ, et al. Comparison of EAP thresholds with MAP levels in the
Nucleus 24 cochlear implant: Data from children. Ear and Hearing. 2000; 21:164–174. [PubMed:
10777023]
Jeon EK, Brown CJ, Etler CP, et al. Comparison of electrically evoked compound action potential
thresholds and loudness estimates for the stimuli used to program the Advanced Bionics cochlear
implant. Journal of the American Academy of Audiology. 2010; 21:16–27. [PubMed: 20085196]
Kwon BJ, van den Honert C. Effect of electrode configuration on psychophysical forward masking in
cochlear implant listeners. Journal of the Acoustical Society of America. 2006; 119(5):2994–3002.
[PubMed: 16708955]
Lai WK, Dillier N. Comparing neural response telemetry amplitude growth functions with loudness
growth functions: Preliminary results. Ear and Hearing. 2007; 28:42S–45S. [PubMed: 17496644]
McKay C, Fewster L, Dawson P. A different approach to using neural response telemetry for
automated cochlear implant processor programming. Ear and Hearing. 2005; 26:38S–44S.
[PubMed: 16082266]
Miller CA, Abbas PJ, Brown CJ. An improved method of reducing stimulus artifact in the electrically
evoked whole-nerve potential. Ear & Hearing. 2000; 21:280–290. [PubMed: 10981604]
Miller CA, Abbas PJ, Rubinstein JT, Robinson BK, Matsuoka AJ, Woodworth G. Electrically evoked
compound action potentials of guinea pig and cat: responses to monopolar, monophasic
stimulation. Hearing Research. 1998; 119:142–154. [PubMed: 9641327]
Patrick JF, Busby PA, Gibson PJ. The development of the Nucleus® Freedom™ cochlear implant
system. Trends in Amplification. 2006; 10(4):175–200. [PubMed: 17172547]
Potts LG, Skinner MW, Gotter BD, et al. Relation between Neural Response Telemetry thresholds, T-
and C-levels, and loudness judgments in 12 adult Nucleus 24 cochlear implant recipients. Ear and
Hearing. 2007; 28:495–511. [PubMed: 17609612]
van Dijk B, Botros A, Battmer R-D, et al. Clinical results of AutoNRT™, a completely automatic
ECAP recording system for cochlear implants. Ear and Hearing. 2007; 28:558–570. [PubMed:
17609616]
Glassman and Hughes Page 15











Screen captures of amplitude growth functions obtained with the clinical software for a
Cochlear (top panel: Custom Sound™ EP) and an Advanced Bionics (AB; bottom panel:
SoundWave™) recipient. Waveforms are shown at left for each device, with N1 and P2
peaks marked by vertical lines for Cochlear and circles for AB. Clinical units of
measurement (CL for Cochlear, CU for AB) are listed to the right of each waveform. For
AB, the amplitude of the response is listed as “EP” in this same location. The right panels
for each manufacturer show the linear regression calculations. For AB, the shaded circles
indicate waveforms that have been included in the regression analysis. The zero intercept of
the calculated line (tNRI = 129) is provided at the top right of this panel. The gray shaded
circle corresponds to the currently selected waveform, (195 CU), which in this example
represents the C-VDT. For Cochlear, the regression analysis is shown with the slope and the
intersection (T-NRT, 168.5975).
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Comparison of computer vs. human picked-peaks for N1 latency (panels A-B), P2 latency
(panels C-D), and peak-to-peak amplitude (panels E-F). Cochlear data are represented by
open circles in the left column and Advanced Bionics data are represented by closed
triangles in the right column. Data points contained in this figure represent only instances
where the computer and expert clinicians were in agreement regarding the presence of an
ECAP response. Pearson correlation coefficients and statistical significance for the figure
are displayed in Table 2. In each panel the solid line represents linear regression analysis
and the dashed line represents unity. Data points falling above unity indicate that the
computer picked longer latencies than humans, while data points falling below the line
indicate the computer picked shorter latencies.
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Individual example of a single amplitude growth function obtained with Neural Response
Imaging (NRI) for an Advanced Bionics subject. Top: computer-picked peaks; bottom:
human-picked peaks for the same data set. In the top panel, the software algorithm marked
peaks (open circles in the graph on the right represent ECAP amplitudes less than 20 μV)
that clinicians identified as artifact within the noise floor of the recording system
(amplitudes set to zero in the bottom right panel). The gray bolded circle in the top panel
corresponds to the selected trace in the left panel. This trace shows a waveform at 152 CU
which has an amplitude of 21 μV (listed as EP in the software). Because the amplitude of
this trace is greater than 20 μV, it has been included in the linear regression analysis. In the
bottom panel, this same trace (bolded circle) has an amplitude of 0 μV, indicating that the
clinicians identified the waveform as artifact, and therefore it was not included in the linear
regression analysis.
Glassman and Hughes Page 18











Comparison of linear regression thresholds (LRT) for human (H-LRT) and computer (C-
LRT) peak-picking methods. Cochlear data are represented by open circles in the left panel
and Advanced Bionics data are represented by closed triangles in the right panel. In each
panel the solid line represents linear regression analysis and the dashed line represents unity.
Pearson correlation coefficients and statistical significance for the figure are displayed in
Table 4.
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Comparison of visual detection thresholds (VDT) for human (H-VDT) and computer (C-
VDT) peak-picking methods. Left panel: Cochlear, right panel: Advanced Bionics. In each
panel the solid line represents linear regression analysis for Cochlear and AB devices, and
the dashed line represents unity. Pearson correlation coefficients and statistical significance
for the figure are displayed in Table 4.
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Comparison between linear regression thresholds (LRT) and visual detection thresholds
(VDT) within each peak-picking method (top: computer, bottom: human) for Cochlear (left
column) and Advanced Bionics (right column). Solid lines represent linear regression
analyses, and dashed lines represent unity. Pearson correlation coefficients and statistical
significance for the figure are displayed in Table 4.
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Comparison of human expert decisions (H-VDT) and fully automated decisions (C-LRT) for
Cochlear (panel A) and Advanced Bionics (panel B) subjects. Solid lines represent linear
regression analyses, and dashed lines represent unity. Pearson correlation coefficients and
statistical significance for the figure are displayed in Table 4.
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Table 2
Pearson correlation coefficients (r-values) and significance (p-values) for data shown in Figure 2.
Computer vs. Human Peak-picking methods Without zero data points With zero data points
r p r p
A: N1 latency (Cochlear) 0.98 <0.001 0.86 <0.001
B: N1 latency (AB) 0.98 <0.001 0.49 <0.001
C: P2 latency (Cochlear) 0.78 <0.001 0.87 <0.001
D: P2 latency (AB) 0.95 <0.001 0.46 <0.001
E: Amplitude (Cochlear) 1.00 <0.001 1.00 <0.001
F: Amplitude (AB) 1.00 <0.001 1.00 <0.001
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Table 3
Summary of mean differences (absolute value) in latency, peak-to-peak amplitude, slope of the regression
line, and ECAP threshold per device type.
Computer-Human Differences Cochlear AB
N1 latency (Fig. 2) 2.65 μsec (9.55 SD) 5.61 μsec (10.22 SD)
P2 latency (Fig. 2) 34.33 μsec (64.37 SD) 17.29 μsec (30.58 SD)
P-P amplitude (Fig. 2) 1.04 μV (2.91 SD) 1.10 μV (1.39 SD)
LR slope (not shown) 0.34 μV/CL (0.42 SD) 0.02 μV/CU (0.04 SD)
Threshold Differences CL μA CU μA
CLRT-HLRT(Fig. 4C-D) 1.10 CL (0.99 SD) 6.18 μA (6.16 SD) 3.61 CU (5.31 SD) 8.67 μA (12.76 SD)
CVDT-HVDT(Fig. 5) 3.25 CL (3.32 SD) 18.41 μA (20.07 SD) 10.64 CU (17.76 SD) 25.58 μA (42.70 SD)
CLRT-CVDT (Fig. 6A-B) 4.29 CL (3.35 SD) 23.36 μA (21.11 SD) 23.10 CU (24.94 SD) 55.54 μA (59.96 SD)
HLRT-HVDT (Fig. 6C-D) 2.68 CL (2.06 SD) 14.38 μA (12.11 SD) 28.54 CU (30.13 SD) 68.60 μA (72.43 SD)
CLRT-HVDT (Fig. 7) 2.70 CL (2.57 SD) 14.97 μA (15.00 SD) 29.57 CU (28.52 SD) 71.09 μA (68.55 SD)
SD = 1 standard deviation; P-P = peak-to-peak; LR = linear regression; CLRT = computer linear regression threshold; HLRT = human linear
regression threshold; CVDT = computer visual detection threshold; HVDT = human visual detection threshold.
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Table 4
Pearson correlation coefficients (r-values) and significance (p-values) for slope and threshold data shown in
Figures 4 to 7.
Cochlear AB
r p r p
Computer-Human LR slope >0.99 <0.001 >0.99 <0.001
CLRT-HLRT (Fig. 4) >0.99 <0.001 0.99 <0.001
CVDT-HVDT (Fig. 5) 0.98 <0.001 0.89 <0.001
CLRT-CVDT (Fig. 6A-B) 0.98 <0.001 0.85 <0.001
HLRT-HVDT (Fig. 6C-D) 0.99 <0.001 0.69 <0.001
CLRT-HVDT (Fig. 7) 0.99 <0.001 0.71 <0.001
LR = linear regression; CLRT = computer linear regression threshold; HLRT = human linear regression threshold; CVDT = computer visual
detection threshold; HVDT = human visual detection threshold. R-values indicated as >0.99 were between 1.0 and 0.99.
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